Colon Cancer Clinical Trial

AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test

Summary

Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay to detect colorectal cancer by collecting blood and stool samples from healthy patients undergoing routine screening colonoscopy and from patients recently diagnosed with colorectal cancer or advanced adenomas.

View Full Description

Full Description

Early detection of cancer combined with effective treatment improves survival and quality of life. Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in the blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay for the early detection of colorectal cancer. The study will collect blood and stool samples from healthy patients undergoing routine screening colonoscopy and from patients recently diagnosed with colorectal cancer or advanced adenomas. A blood-based test for colorectal cancer and pre-cancerous lesions could offer an accurate, convenient, and patient-friendly screening option for current and future generations, and, in doing so, could save and improve lives by increasing adherence and early detection.

Freenome is looking for three types of patients in this study:

Cohort A:

People ages 50-84 who have been recently diagnosed with (or strong clinical suspicion for) colorectal cancer or advanced adenoma. Blood samples must be collected before any cancer treatment has been initiated.

Cohort B:

People ages 50-84 undergoing routine screening colonoscopies for colorectal cancer as part of their regular medical check-ups. Blood samples must be collected before bowel preparation for the colonoscopy.

Cohort C:

People 18 years or older who have been recently diagnosed with (or strong clinical suspicion for) colorectal cancer or advanced adenoma. Blood samples must be collected before any cancer treatment has been initiated.

View Eligibility Criteria

Eligibility Criteria

COHORT A

Inclusion Criteria:

50-84 years of age (inclusive) at the time of screening
Recently diagnosed with (or strong clinical suspicion for) primary colorectal cancer or advanced adenoma with plans to surgically or endoscopically remove the target lesion(s)
At least 7 days before but no more than 6 months after the most recent colonoscopy
Able and willing to provide blood and stool (optional) samples per protocol
Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study

Key Exclusion Criteria:

Personal history of colorectal cancer, colorectal adenomas (excluding non-adenomatous (e.g., hyperplastic polyps)) or aerodigestive tract cancer (other than most recent diagnosis)
Colonoscopy within the previous 9 years (other than most recent diagnosis)
Overt rectal bleeding within the previous 30 days
Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study.
Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy.
If female, known to be pregnant.

COHORT B

Inclusion Criteria:

50-84 years of age (inclusive) at the time of screening
Planning to undergo a screening colonoscopy within 75 days after providing signed informed consent
Able and willing to provide blood and stool (optional) samples per protocol
Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study

Key Exclusion Criteria:

Personal history of colorectal cancer, colorectal adenoma (excluding non-adenomatous (e.g., hyperplastic polyps)) or aerodigestive tract cancer
Colonoscopy within the previous 9 years
Overt rectal bleeding within the previous 30 days
Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study.
Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy.
If female, known to be pregnant.

COHORT C

Inclusion Criteria:

At least 18 years of age (inclusive) at the time of screening
Recently diagnosed with (or strong clinical suspicion for) primary colorectal cancer or advanced adenoma with plans to surgically or endoscopically remove the target lesion(s)
At least 7 days before but no more than 6 months after the most recent colonoscopy
Able and willing to provide blood and stool (optional) samples per protocol
Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study

Exclusion Criteria:

Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study.
Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy.
If female, be known to be pregnant.

Study is for people with:

Colon Cancer

Estimated Enrollment:

3275

Study ID:

NCT03688906

Recruitment Status:

Completed

Sponsor:

Freenome Holdings Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 30 Locations for this study

See Locations Near You

Clinical Research Associates
Huntsville Alabama, 35801, United States
Del Sol Research Management
Chandler Arizona, 85224, United States
Del Sol Research Management,
Tucson Arizona, 85710, United States
Del Sol Research Management
Tucson Arizona, 85745, United States
Preferred Research Partners
Little Rock Arkansas, 72211, United States
Precision Research Institute
Chula Vista California, 91910, United States
Diverse Research Solutions
Oxnard California, 93030, United States
Precision Research Institute
San Diego California, 92114, United States
Gastroenterology Associates of Fairfield County
Bridgeport Connecticut, 06606, United States
Palmetto Research
Hialeah Florida, 33016, United States
Clinical Research of Homestead
Homestead Florida, 33030, United States
Advanced Gastroenterology Associates, LLC
Palm Harbor Florida, 34684, United States
Rockford Gastroenterology
Rockford Illinois, 61107, United States
Delta Research Partners
Bastrop Louisiana, 71220, United States
New Orleans Research Institute
Metairie Louisiana, 70006, United States
Louisiana Research Center
Shreveport Louisiana, 71105, United States
Commonwealth Clinical Studies
Brockton Massachusetts, 02302, United States
Quality Clinical Research
Omaha Nebraska, 68114, United States
Asheville Gastroenterology Associates
Asheville North Carolina, 28801, United States
University of North Carolina at Chapel Hill
Chapel Hill North Carolina, 27599, United States
Cumberland Research Associates
Fayetteville North Carolina, 28304, United States
Wake Research Associates
Raleigh North Carolina, 27612, United States
Trial Management Associates
Wilmington North Carolina, 28403, United States
The Jackson Clinic
Jackson Tennessee, 38305, United States
Advanced Research Institute
Ogden Utah, 84405, United States
Gastroenterology Associates of Tidewater
Chesapeake Virginia, 23320, United States
Verity Research Inc
Fairfax Virginia, 22031, United States
Digestive and Liver Disease Specialists
Norfolk Virginia, 23502, United States
Washington Gastroenterology
Bellevue Washington, 98004, United States
Forzani and MacPhail Colon Cancer Screening Centre
Calgary Alberta, T2N 4, Canada

How clear is this clinincal trial information?

Study is for people with:

Colon Cancer

Estimated Enrollment:

3275

Study ID:

NCT03688906

Recruitment Status:

Completed

Sponsor:


Freenome Holdings Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider